Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PROK
Strong SellProKidney Corp. · Healthcare · United States · $731M · Avg Vol: $2M/d
COMPANY DESCRIPTION
ProKidney Corp. is a clinical-stage biotechnology company developing an autologous cell therapy product, Renal Autologous Cell Therapy (REACT®), for chronic kidney disease (CKD). The company's innovative approach utilizes a patient's own renal cells to slow or reverse the progression of CKD. Its competitive advantage lies in its proprietary cell therapy platform and its potential to offer a disease-modifying treatment in a large, underserved patient population.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 76.0K | 0.9M | 1075.0% | 0.8M | 0.5M | 0.5M | -25.6% |
| EPS | -0.07 | -0.17 | -0.62 | -0.52 | — | -0.55 | -0.56 | -0.59 | — |
| Shares | 205.2M | 205.2M | 128.1M | 141.8M | -30.9% | — | — | — | — |
| Debt | 2.4M | 4.4M | 3.2M | 4.0M | 18.9% | 3.5M | — | — | — |
| Equity | -1.1B | -1.1B | -995.0M | -1.0B | — | — | — | — | — |
| Op CF | -77.1M | -90.1M | -126.4M | -120.1M | — | -141.2M | — | — | — |
| Inv CF | -1.7M | -330.0M | 20.4M | 104.0M | — | — | — | — | — |
| Fin CF | 548.5M | -9.6M | 144.4M | 25.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PROK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PROK | ProKidney Corp.(you) | $731M | 4 | Strong Sell |
| OLMA | Olema Pharmaceuticals, Inc. | $899M | 5 | Strong Sell |
| PRME | Prime Medicine, Inc. | $655M | 2 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 9 | Strong Sell |
| ATTO | Attovia Therapeutics, Inc. | $891M | 7 | Strong Sell |
| CAPR | Capricor Therapeutics, Inc. | $558M | 3 | Strong Sell |
| OBX | Obsidian Therapeutics, Inc. | $1.0B | 5 | Strong Sell |
| VOGX | Vogenx, Inc. | $504M | 5 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $586M | 8 | Strong Sell |
| WVE | Wave Life Sciences, Inc. | $993M | 2 | Strong Sell |
Peer medians: ROE -25.6% · P/E 28.9x · Gross margin 58.7%